PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence.
Phase of Trial: Phase III
Latest Information Update: 02 May 2014
At a glance
- Drugs Cintredekin besudotox (Primary) ; Carmustine polifeprosan 20 wafer
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms PRECISE
- Sponsors INSYS Therapeutics, Inc
- 03 Jun 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 03 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Apr 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History